SCHEMBL1229680

SCHEMBL1229680

O=C(O)c1sccc1Nc1ccnc2[nH]ccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.44
JAK1 P23458 1/20 0.44
TYK2 P29597 1/20 0.44
ROCK1 Q13464 5/20 0.43
PTPN2 P17706 1/20 0.42
PTPN1 P18031 1/20 0.42
ROCK2 O75116 5/20 0.41
PRKD3 O94806 3/20 0.41
PRKACA P17612 3/20 0.41
PRKCQ Q04759 3/20 0.41
PRKCD Q05655 2/20 0.41
PKN2 Q16513 2/20 0.41
PRKD2 Q9BZL6 2/20 0.41
MAP4K4 O95819 2/20 0.41
CSNK1A1 P48729 2/20 0.41
CDK9 P50750 2/20 0.41
CIT O14578 1/20 0.41
PRKCB P05771 1/20 0.41
PRKCA P17252 1/20 0.41
CSNK2A2 P19784 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1231319 0.88 JAK2 (0.46) JAK2JAK1TYK2ROCK1ROCK2
SCHEMBL1230522 0.88 IKBKB (0.46) JAK2JAK1TYK2ROCK1ROCK2
SCHEMBL13517118 0.85 JAK2 (0.41) JAK2JAK1TYK2ROCK1ROCK2
SCHEMBL1231735 0.84 ROCK1 (0.41) ROCK1ROCK2PRKD3PRKACAPRKCQ
SCHEMBL1231358 0.84 JAK2 (0.38) JAK2JAK1TYK2ROCK1ROCK2
SCHEMBL1230543 0.83 PTPRC (0.41) JAK2JAK1TYK2ROCK1BMPR1A
SCHEMBL1229684 0.82 ALDH1A1 (0.40) JAK2JAK1TYK2ROCK1ROCK2
SCHEMBL19390351 0.82 ADORA2A (0.45) JAK2JAK1TYK2ROCK1PKN2
SCHEMBL13517059 0.82 ADORA2A (0.43) JAK2JAK1TYK2ROCK1PKN2
SCHEMBL12901040 0.81 AKT1 (0.50) JAK2JAK1TYK2ROCK1ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2462141-B1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2017-09-27 EP claimed
US-9023847-B2 Azaheterocyclic compounds MERCK PATENT GMBH (DE) 2015-05-05 US claimed
CN-102471338-B Novel azaheterocyclic compounds MERCK PATENT GMBH 2014-07-02 CN claimed
US-20120277228-A1 Novel Azaheterocyclic Compounds MERCK PATENT GMBH (DE) 2012-11-01 US claimed
EP-2462141-A1 NOVEL AZAHETEROCYCLIC COMPOUNDS Merck Patent GmbH (DE) 2012-06-13 EP claimed
WO-2011017009-A1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2011-02-10 WO claimed
EP-2462141-B1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2017-09-27 EP disclosed
EP-2462141-B1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2017-09-27 EP disclosed
US-9023847-B2 Azaheterocyclic compounds MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023847-B2 Azaheterocyclic compounds MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
CN-102471338-B Novel azaheterocyclic compounds MERCK PATENT GMBH 2014-07-02 CN disclosed
US-20120277228-A1 Novel Azaheterocyclic Compounds MERCK PATENT GMBH (DE) 2012-11-01 US disclosed
EP-2462141-A1 NOVEL AZAHETEROCYCLIC COMPOUNDS Merck Patent GmbH (DE) 2012-06-13 EP disclosed
CN-102471338-A Novel azaheterocyclic compounds MERCK PATENT GMBH 2012-05-23 CN disclosed
WO-2011017009-A1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2011-02-10 WO disclosed
WO-2011017009-A1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277228-A1 Novel Azaheterocyclic Compounds PCNA, MCL1, MYC JAK2 633/4885JAK1 1151/4885TYK2 3049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.